Nature's Sunshine Products (NATR) Earnings Analysis
Nature's Sunshine Products (NATR) next reports earnings on 2026-07-30, consensus EPS 0.27 USD. Last quarter (2026-05-07) it beat with EPS 0.3 USD vs 0.205 USD est (+46.3%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E 18.76.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NATR next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | 0.27 USD |
| Revenue estimate | 0.12B |
NATR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 0.3 USD | 0.205 USD | +46.3% | Beat |
| 2026-03-10 | 0.3 USD | 0.185 USD | +62.2% | Beat |
| 2025-11-06 | 0.36 USD | 0.19 USD | +89.5% | Beat |
| 2025-07-31 | 0.35 USD | 0.18 USD | +94.4% | Beat |
| 2025-03-11 | -0.02 USD | 0.2 USD | -110% | Miss |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
NATR valuation and analyst view
| Trailing P/E | 18.76 |
|---|---|
| Trailing EPS | 1.135 USD |
| Price / book | 2.19 |
| Dividend yield | 0.00% |
| Market cap | 0.37B |
| Analyst consensus | Buy (2 buy / 2 hold / 0 sell) |
| Avg price target | 37 USD |
Related research pages
Frequently asked questions
When is Nature's Sunshine Products (NATR)'s next earnings date?
Nature's Sunshine Products is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 0.27 USD and revenue estimate of 0.12B.
Did NATR beat earnings last quarter?
In its 2026-05-07 report, NATR posted EPS of 0.3 USD versus a 0.205 USD estimate — a beat of 46.3%.
What is NATR's earnings track record?
Over the last 5 reported quarters with consensus data, NATR beat estimates 4 times (80%).
What is NATR's current P/E ratio and EPS?
NATR trades at a trailing P/E of 18.76 on trailing EPS of 1.1352585321310353 USD.
What do analysts rate NATR?
Analyst consensus is "Buy" across 4 ratings (0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 37 USD.